Synonyms: OPC 34712 | OPC-34712 | Rxulti®
brexpiprazole is an approved drug (FDA (2015), EMA (2018))
Compound class:
Synthetic organic
Comment: Brexpiprazole is a serotonin-dopamine activity modulator (SDAM) [2].
Ligand Activity Visualisation ChartsThese are box plot that provide a unique visualisation, summarising all the activity data for a ligand taken from ChEMBL and GtoPdb across multiple targets and species. Click on a plot to see the median, interquartile range, low and high data points. A value of zero indicates that no data are available. A separate chart is created for each target, and where possible the algorithm tries to merge ChEMBL and GtoPdb targets by matching them on name and UniProt accession, for each available species. However, please note that inconsistency in naming of targets may lead to data for the same target being reported across multiple charts. ✖View more information in the IUPHAR Pharmacology Education Project: brexpiprazole |
|
References |
1. Citrome L. (2015)
Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?. Int J Clin Pract, 69 (9): 978-97. [PMID:26250067] |
2. Maeda K, Sugino H, Akazawa H, Amada N, Shimada J, Futamura T, Yamashita H, Ito N, McQuade RD, Mørk A et al.. (2014)
Brexpiprazole I: in vitro and in vivo characterization of a novel serotonin-dopamine activity modulator. J Pharmacol Exp Ther, 350 (3): 589-604. [PMID:24947465] |